Results 111 to 120 of about 1,361,764 (281)

Progress in bone tissue engineering biomaterials: Development, challenges, and prospects

open access: yesVIEW, EarlyView.
Scheme 1 Application of biomaterials in immunomodulation during bone tissue engineering. Abstract Bone defect repair remains a major clinical challenge in orthopedics. Over 2 million cases caused by trauma, tumors, and other factors occur annually, with large‐scale defects posing a particular bottleneck due to limited self‐healing capacity.
Yuanbin Zhang   +7 more
wiley   +1 more source

Red lines and green lights: Gene therapy for inherited erythroid disorders beyond the haemoglobinopathies

open access: yesBritish Journal of Haematology, EarlyView.
Gene therapy is revolutionizing treatment paradigms for haemoglobinopathies, establishing a translational framework for disorders that impact red blood cell development. In their paper, Joshi et al. describe the preclinical and early clinical landscape of gene therapies for non‐haemoglobinopathy erythroid disorders and highlight common thematic ...
Gaurav Joshi   +3 more
wiley   +1 more source

Autologous Bone Marrow Stem Cell Infusion (AMBI) therapy for Chronic Liver Diseases

open access: yesJournal of Stem Cells and Regenerative Medicine, 2007
Liver Cirrhosis is the end stage of chronic liver disease which may happen due to alcoholism, viral infections due to Hepatitis B, Hepatitis C viruses and is difficult to treat.
Rajkumar JS   +6 more
doaj  

Prognostic impact of blood Epstein–Barr virus‐DNA in patients with peripheral T‐cell lymphoma, not otherwise specified

open access: yesBritish Journal of Haematology, EarlyView.
Summary Peripheral T‐cell lymphoma, not otherwise specified (PTCL‐NOS), is a heterogeneous nodal T‐ and natural killer (NK)‐cell lymphoma with limited prognostic biomarkers. A subset of PTCL‐NOS characterized by Epstein–Barr virus (EBV) involvement in tumour cells has recently been recognized as EBV‐positive nodal T‐ and NK‐cell lymphoma (EBV+ nPTCL ...
Hyunseok Yoon   +14 more
wiley   +1 more source

A SUCCESSFUL CASE OF PRIMARY PLASMA CELL LEUKEMIA TREATED WITH DARATUMUMAB-BASED THERAPY FOLLOWED BY AUTOLOGOUS BONE MARROW TRANSPLANTATION

open access: yesHematology, Transfusion and Cell Therapy
Case report: Context: Primary plasma cell leukemia is a rare and aggressive variant of plasma cell neoplasm, and its diagnosis is based on the percentage (≥ 20%) of circulating plasma cells in the peripheral blood.
Aferdita UKIMERAJ   +2 more
doaj   +1 more source

Comorbid conditions after allogeneic haematopoietic stem cell transplantation in young adults in Germany—A prospective, multicentre trial

open access: yesBritish Journal of Haematology, EarlyView.
Summary Young adults (YA) are particularly affected by comorbid conditions following allogeneic haematopoietic stem cell transplantation (alloHSCT), as they have to live with them for many years. This is the first multicentre prospective study investigating sequelae after alloHSCT in YA in Germany. In total, 107 patients who survived relapse‐free until
Pauline Rocke   +9 more
wiley   +1 more source

Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real‐life study from European Myeloma Network (EMN) Italy

open access: yesBritish Journal of Haematology, EarlyView.
Summary The extensive use of lenalidomide (Len) in the first‐line treatment of multiple myeloma (MM) has resulted in an increased frequency of patients who have been exposed or are refractory to Len (Len‐R) at first relapse. However, the outcome of Len‐R patients treated at first relapse after autologous haematopoietic stem cell transplantation (AHSCT)
Gregorio Barilà   +48 more
wiley   +1 more source

Real‐world outcomes of ide‐cel and cilta‐cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria

open access: yesBritish Journal of Haematology, EarlyView.
Summary B‐cell maturation antigen‐directed chimeric antigen receptor (CAR) T cells have revolutionized the treatment of relapsed/refractory multiple myeloma. However, no randomized head‐to‐head comparison of idecabtagene vicleucel (ide‐cel) and ciltacabtagene autoleucel (cilta‐cel) is available, and real‐world data suggest differences in efficacy and ...
Irene Strassl   +23 more
wiley   +1 more source

Can't Patch Everything: Personalized Medicine for Cell Therapy in Dilated Cardiomyopathy

open access: yes, 2021
Journal of the American Heart Association, EarlyView.
Andrew Sundin   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy